Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,
Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Schenk J, Kayser A, Wiedenmann B, Tacke F, Roderburg C,
Keywords: NEN G3, Chemotherapy, Platinum, NEC G3, NET G3,
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,
Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET, Tumor Dosimetry, Response,
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burg M,
Keywords: 68Ga-DOTATATE PET-CT, Tumor Dosimetry, SUV predictors,